# Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma

> **NCT01907308** · PHASE2 · WITHDRAWN · sponsor: **University of Colorado, Denver**

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** AMG 386
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01907308
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor's decision to terminate the study
- **Last updated:** 2014-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01907308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01907308, "Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01907308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*